GENPREX INC (GNPX)
US3724462037 - Common Stock
GENPREX INC
NASDAQ:GNPX (11/22/2024, 8:00:00 PM)
After market: 1.11 +0.01 (+0.91%)1.1
-0.04 (-3.51%)
Company Profile
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas and currently employs 26 full-time employees. The company went IPO on 2018-03-29. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. The company conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Company Info
GENPREX INC
1601 Trinity Street, Bldg. B, Suite 3.322
Austin TEXAS 78712
P: 15125377997
CEO: J. Rodney Varner
Employees: 26
Website: https://www.genprex.com/
GNPX News
12 days ago - ChartmillHere are the top movers in Tuesday's session, showcasing the stocks with significant price changes.Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
12 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Let's have a look at the top gainers and losers in the middle of the day of today's session.
2 months ago - Genprex, Inc.Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
2 months ago - Genprex, Inc.Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
3 months ago - Get NewsPlanned Spin-Out to Focus on Gene Therapy for Type-1 and Type-2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex, Inc. (Nasdaq: GNPX)3 months ago - Genprex, Inc.Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes/PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies...
GNPX Twits
Here you can normally see the latest stock twits on GNPX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
